company background image
ALQGC logo

Quantum Genomics Société Anonyme ENXTPA:ALQGC Stock Report

Last Price

€0.10

Market Cap

€3.6m

7D

-0.2%

1Y

-20.5%

Updated

25 Mar, 2024

Data

Company Financials +

Quantum Genomics Société Anonyme

ENXTPA:ALQGC Stock Report

Market Cap: €3.6m

ALQGC Stock Overview

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases.

ALQGC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Quantum Genomics Société Anonyme Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Quantum Genomics Société Anonyme
Historical stock prices
Current Share Price€0.10
52 Week High€0.21
52 Week Low€0.08
Beta0.71
1 Month Change2.78%
3 Month Change-2.08%
1 Year Change-20.46%
3 Year Change-97.74%
5 Year Change-98.06%
Change since IPO-99.48%

Recent News & Updates

Recent updates

Shareholder Returns

ALQGCFR BiotechsFR Market
7D-0.2%1.7%-0.3%
1Y-20.5%-2.2%10.1%

Return vs Industry: ALQGC underperformed the French Biotechs industry which returned -2.1% over the past year.

Return vs Market: ALQGC underperformed the French Market which returned 10.2% over the past year.

Price Volatility

Is ALQGC's price volatile compared to industry and market?
ALQGC volatility
ALQGC Average Weekly Movement9.9%
Biotechs Industry Average Movement6.4%
Market Average Movement4.3%
10% most volatile stocks in FR Market9.9%
10% least volatile stocks in FR Market2.2%

Stable Share Price: ALQGC has not had significant price volatility in the past 3 months.

Volatility Over Time: ALQGC's weekly volatility has decreased from 19% to 10% over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
20054Jean-Philippe Milonhttps://www.quantum-genomics.com

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs.

Quantum Genomics Société Anonyme Fundamentals Summary

How do Quantum Genomics Société Anonyme's earnings and revenue compare to its market cap?
ALQGC fundamental statistics
Market cap€3.60m
Earnings (TTM)-€3.17m
Revenue (TTM)€19.80k

182.1x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALQGC income statement (TTM)
Revenue€19.80k
Cost of Revenue€1.44m
Gross Profit-€1.42m
Other Expenses€1.75m
Earnings-€3.17m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.091
Gross Margin-7,169.57%
Net Profit Margin-16,018.12%
Debt/Equity Ratio622.2%

How did ALQGC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.